PERTH, Australia – Australia’s Atomo Diagnostics Pty. Ltd. is preparing to raise AU$30 million (US$11.7 million) in an initial public offering on Australia’s Securities Exchange (ASX) that will enable it to ramp up manufacturing for rapid self-tests for COVID-19. The Sydney-based company is working with several multinational diagnostics companies to develop the new COVID-19 blood tests, which would be integrated with Atomo’s existing rapid test platform currently used for HIV screening.

Design Therapeutics Inc., a San Diego startup developing new therapies for degenerative disorders caused by nucleotide repeat expansions, has raised $45 million in series A financing.

Sight Sciences Inc., of Menlo Park, Calif., scooped up $30 million in a series E preferred stock financing round that was led by D1 Capital Partners. The funds are earmarked to further advance clinical and operational development and support commercial expansion of the company’s Omni surgical and Tearcare systems.

DUBLIN – The middle of a pandemic may not be the optimal time to launch an oncology-focused company, but Klosterneuburg, Austria-based Oncoone Research & Development GmbH unveiled a €13 million (US$14.1 million) series A round Wednesday, March 18, and laid out plans to develop several different approaches to targeting an immunologically distinct form of a ubiquitous inflammatory cytokine, which is unique to cancer cells and which is associated with a poor prognosis.